title: Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.
abstract: Cytarabine (cytosine arabinoside) is one of the most effective drugs for the treatment of acute myeloid leukemia. The standard dose of cytarabine used to treat this leukemia is 100 mg per square meter. In an attempt to improve the effectiveness of cytarabine against acute myeloid leukemia, a high-dose treatment (3,000 mg per square meter) was introduced into therapy. The side effects of high-dose cytarabine was a major concern, especially its neurological toxicity. A review of recent clinical trials indicates that this high-dose cytarabine can be replaced by the intermediate-dose of 1,000 mg per square meter without loss of efficacy and with less toxicity. This is an important step to improve the efficacy of cytarabine for the treatment of acute myeloid leukemia. Despite the improvements in the therapy for this leukemia, the current overall survival rate for adult patients is less than 30%. To optimize the cytarabine therapy, it is important to determine how some leukemic stem cells survive treatment. Preclinical data suggest that survival of the leukemic stem cells could be due to the long 12 hour interval between infusions of cytarabine, which permits some leukemic cells to escape its S phase specific action. Among the other factors that can lead to leukemic cell survival are the high levels in the liver and spleen of cytidine deaminase, the enzyme that inactivates cytarabine and drug resistance due to deficiency in deoxycytidine kinase, the enzyme that activates the prodrug, cytarabine. Several approaches are proposed in this commentary to overcome these impediments with the goal of increasing the effectiveness of cytarabine for the treatment of acute myeloid leukemia.
authors.affiliation: Département de pharmacologie, Université de Montréal and Service d'hématologie/oncologie, CHU-Saint-Justine, 3175 Cote Sainte-Catherine, Montréal QC H3T 1C5, Canada.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Momparler
keywords: Acute myeloid leukemia; Cytarabine; Cytosine arabinoside; Drug resistance; Pharmacology
references.citation: N Engl J Med. 1999 Sep 30;341(14):1051-62
references.pmid: 10502596
references.citation: Leukemia. 2010 Nov;24(11):1859-66
references.pmid: 20739953
references.citation: Cancer Chemother Pharmacol. 1984;13(3):191-4
references.pmid: 6207950
references.citation: Clin Cancer Res. 2005 Sep 15;11(18):6520-7
references.pmid: 16166428
references.citation: Blood. 2011 Aug 11;118(6):1472-80
references.pmid: 21613261
references.citation: Cancer Chemother Pharmacol. 1998;42(5):373-8
references.pmid: 9771951
references.citation: Cancer Res. 1987 Jun 1;47(11):3005-11
references.pmid: 3471322
references.citation: Cancer Res. 1973 Nov;33(11):2816-20
references.pmid: 4518302
references.citation: J Neurochem. 2012 Oct;123(2):217-25
references.pmid: 22845688
references.citation: Semin Oncol. 1987 Jun;14(2 Suppl 1):231-7
references.pmid: 2438776
references.citation: Blood. 2013 Jan 3;121(1):26-8
references.pmid: 23287624
references.citation: Blood. 1990 Dec 1;76(11):2191-7
references.pmid: 2257293
references.citation: Cancer Res. 1978 Jun;38(6):1730-3
references.pmid: 274175
references.citation: Expert Opin Pharmacother. 2009 Apr;10(5):839-46
references.pmid: 19351232
references.citation: Int J Cancer. 1991 Oct 21;49(4):573-6
references.pmid: 1917159
references.citation: Cancer Chemother Pharmacol. 1989;25(1):51-4
references.pmid: 2480188
references.citation: Oncol Res. 2008;17(5):223-30
references.pmid: 18980019
references.citation: Leuk Res. 2013 Aug;37(8):980-4
references.pmid: 23660386
references.citation: Leuk Res. 1984;8(6):1043-9
references.pmid: 6083417
references.citation: Leuk Res. 2011 Jan;35(1):110-8
references.pmid: 20510451
references.citation: Cancer Res. 1988 Mar 1;48(5):1337-42
references.pmid: 3342412
references.citation: Oncogene. 2006 Aug 28;25(38):5220-7
references.pmid: 16936740
references.citation: Semin Oncol. 2012 Feb;39(1):97-108
references.pmid: 22289496
references.citation: Neoplasia. 2013 Mar;15(3):239-48
references.pmid: 23479503
references.citation: J Clin Oncol. 1983 Dec;1(12):763-71
references.pmid: 6668493
references.citation: Blood. 1983 Aug;62(2):361-9
references.pmid: 6223674
references.citation: Leukemia. 1994 May;8(5):780-5
references.pmid: 7514246
references.citation: Blood. 1994 Nov 1;84(9):3148-57
references.pmid: 7949187
references.citation: Cancer Res. 1982 Apr;42(4):1587-94
references.pmid: 6949642
references.citation: Cancer Res. 1974 Aug;34(8):1775-87
references.pmid: 4526298
references.citation: Cancer. 1979 Oct;44(4):1189-93
references.pmid: 498009
references.citation: N Engl J Med. 2011 Mar 17;364(11):1027-36
references.pmid: 21410371
references.citation: J Clin Invest. 2011 Jan;121(1):384-95
references.pmid: 21157036
references.citation: Cancer Treat Rep. 1984 Sep;68(9):1143-8
references.pmid: 6592037
references.citation: Cell Cycle. 2011 Jul 15;10(14):2323-30
references.pmid: 21654193
references.citation: Oncotarget. 2012 Oct;3(10):1137-45
references.pmid: 23087155
references.citation: Leukemia. 2011 Nov;25(11):1739-50
references.pmid: 21701495
references.citation: Curr Hematol Malig Rep. 2013 Jun;8(2):141-8
references.pmid: 23666364
references.citation: Biochim Biophys Acta. 1968 Jul 23;161(2):481-93
references.pmid: 4174433
references.citation: J Clin Oncol. 1987 Jun;5(6):927-32
references.pmid: 3585447
references.citation: Biochim Biophys Acta. 2013 Jan;1832(1):114-20
references.pmid: 23046813